Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

NCT03402815 is registered in ClinicalTrials.gov with University Of Perugia as lead sponsor.

NCT NCT03402815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
Lead sponsor
University Of Perugia
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2015
Completion date
September 30, 2017
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, cardiovascular risk factor, hiv infection with other conditions, inflammation